A trio of abstracts presented at ACR Convergence 2024, the annual meeting of the American College of Rheumatology, bear out the benefits of bimekizumab (Bimzelx; UCB Pharma) for use against active ...

The American College of Rheumatology (ACR) 2024 Convergence has just concluded, showcasing significant advancements and ...

TNX-102 SL, a sublingual cyclobenzaprine HCl formulation, is safe and effective for treating fibromyalgia symptoms, according to study results presented at the American College of Rheumatology (ACR) ...

A total of 135 participants were randomly assigned to receive inebilizumab (300-mg infusions on days 1 and 15 and week 26) or ...

Colchicine fails to improve knee pain, function, or size of synovial effusions with painful knee osteoarthritis (OA), ...

Long-term treatment with anifrolumab significantly reduced the rate of organ damage compared with SOC among patients with SLE ...

A drug in advanced development for myasthenia gravis also showed promise as a treatment for primary Sjögren's syndrome, a ...

Cellular immunotherapy specialist Fate Therapeutics soared as much as 73%, and closed up 12.45 at $2.27 yesterday, after it ...

Initial Clinical Data from Phase 1 Autoimmunity Study of FT819 1XX CAR T-cell Product Candidate to be Presented in 4Q24; ...

To make use of the fresh 1win added bonus code, you must put it to use within the membership techniques. 1win: Join ACR Casino poker’s OSS XL Leaderboard Battle to have an opportunity to Win over ...

at 11:05 Immunis Successfully Completes its Phase 1/2a Clinical Trial Targeting Muscle Atrophy Immunis ... the positive Phase 3 PHOENYCS GO data reported by UCB and Biogen during ACR Convergence 2024.

Most patients with rheumatoid arthritis or spondyloarthritis had significant antibody responses to COVID vaccine boosters, whether or not their immunomodulatory medications were held.